Almost one year after the medical use of cannabis was legalised in the UK, on 1 November 2018, this special report looks at why most patients are not yet able to access this treatment.
One year since UK law changed to enable medical cannabis to be prescribed, researchers are exploring the drug’s potential for treating post-traumatic stress disorder, schizophrenia and attention deficit hyperactivity disorder.
Medical cannabis was legalised in the UK on 1 November 2018, but the regulations around its use and supply remain strict. Here is a quick update about how it is being used in the NHS and what benefits it may or may not offer.
Medical cannabis: what will pharmacy's role be?Subscription
How the UK has realised the benefits of medical cannabis and the involvement pharmacists could have in its supply.
A quick guide to medical cannabisSubscription
With medical cannabis now legal in 44 countries around the world, and the UK likely to follow suit, here is what pharmacists need to know.
The UK government recognises that cannabis-based medicines could benefit children with epilepsy, but more robust effectiveness and safety data is required before the products can become widely available.
The bar must not be lowered for medical cannabisSubscription
There have been calls to loosen regulations around medical cannabis to increase access for those who need it, but the government must resist and view cannabis with the same scrutiny as any other new medicine.
The legalisation of medical cannabis has offered a chance to put pharmacy at the forefront of health and patient care, where it belongs.
Hospital trust bureaucracy and doctors’ ignorance are to blame for the lack of prescriptions for medical cannabis being issued on the NHS, despite its reclassification for medical use in November 2018.
Beyond cannabis: why we should look at legalising other illegal drugs for medical use to benefit patientsSubscription
The UK government has finally realised the value of cannabis as a medicine, but it must not ignore the medical potential of other Schedule 1 drugs, such as psilocybin, LSD and MDMA.